Providing appropriate risk information on genome editing for patients

Trends in Biotechnology

Volumn 34, Issue 2, 2016, Pages 86-90

  Araki, Motoko ^a   Ishii, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Clinical application; CRISPR Cas9; Genome editing; Informed consent; Off target mutation; Society

Indexed keywords

ADENOVIRUS VECTOR; CD34 ANTIGEN; GENOMIC DNA; ORNITHINE CARBAMOYLTRANSFERASE; RETROVIRUS VECTOR; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE;

BIOTECHNOLOGY; CELL CULTURE; CELL TRANSPLANTATION; CHROMOSOME TRANSLOCATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; COMPARATIVE GENOMIC HYBRIDIZATION; COST EFFECTIVENESS ANALYSIS; DOUBLE STRANDED DNA BREAK; EX VIVO GENE TRANSFER; GENE DISRUPTION; GENE EXPRESSION; GENE INSERTION; GENE THERAPY; GENETIC RISK; GENOME EDITING; GENOTYPE; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFERTILITY THERAPY; INFORMED CONSENT; MEDICAL INFORMATION; META ANALYSIS (TOPIC); NONHUMAN; NOTE; PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; RISK INFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ACCEPTANCE; SOMATIC CELL; SOMATIC EDITING THERAPY; SPONTANEOUS MUTATION; T CELL LEUKEMIA; VIRUS GENOME; VIRUS SHEDDING; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ZYGOTE; ADVERSE EFFECTS; GENE TARGETING; MUTATION; PATIENT ATTITUDE; PROCEDURES; RISK;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENE TARGETING; GENETIC THERAPY; GENOME, HUMAN; HUMANS; MUTATION; PATIENT ACCEPTANCE OF HEALTH CARE; RISK;

EID: 84960374079     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.12.002     Document Type: Note

References (20)

1. Kimmelman J. The ethics of human gene transfer. Nat. Rev. Genet. 2008, 9:239-244.
2. Hacein-Bey-Abina S., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118:3132-3142.
3. Tebas P., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370:901-910.
4. Cong L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
5. Cho S.W., et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014, 24:132-141.
6. Tsai S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 2015, 33:187-197.
7. Kim D., et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 2015, 12:237-243.
8. Araki M., et al. Caution required for handling genome editing technology. Trends Biotechnol. 2014, 32:234-237.
9. Joung J.K. Unwanted mutations: standards needed for gene-editing errors. Nature 2015, 523:158.
10. Lander E.S. Brave new genome. N. Engl. J. Med. 2015, 373:5-8.
11. Ishii T. Germline genome-editing research and its socioethical implications. Trends Mol. Med. 2015, 21:473-481.
12. + T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26:808-816.
13. Liang P., et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015, 6:363-372.
14. Kumar A., et al. Whole genome prediction for preimplantation genetic diagnosis. Genome Med. 2015, 7:35.
15. Li H., et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011, 475:217-221.
16. Ran F.A., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015, 520:186-191.
17. Bloom K., et al. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol. Ther. 2013, 21:1889-1897.
18. Yla-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol. Ther. 2015, 23:217-218.
19. ICH (2009) ICH Considerations General Principles to Address Virus and Vector( http://www.ich.org/products/consideration-documents.html.)
20. Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 2015, 33:890-891.